Then there were two: BeOne moves beyond single-blockbuster dependence
The company’s Sonrotoclax is the first newly approved BCL-2 inhibitor in the U.S. in nearly a decade, giving BeOne a potential new hit beyond its Zanubrutinib blood cancer therapy Key…
Zai Lab under pressure over clinical results and rival drugs
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products Key Takeaways: The survival benefits for…
Cancer drug maker Genfleet joins Hong Kong IPO influx
The biotech can boast a long list of big-name backers and has brought a promising drug to the market with its partner Innovent, but its cash reserves are dwindling Key…
Drug Startups Eye Quicker Profits Under China’s New Fast-Track Approvals
Key changes designed to bring cutting-edge drugs more quickly to market have yet to ignite significant rally for money-losing startups Key takeaways: New fast-track approval system could bring cutting-edge drugs…
Recent Articles
RELATED ARTICLES
-
Jacobio Pharma poised to turn a profit from precision cancer drugs
-
InnoCare hits profit milestone, enters new phase with global expansion, strong pipeline
9969.HK688428.SHG
- Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
- Mega licensing deal lifts 3SBio profits but core sales slip
- A healthy return: drug spin-off nets Keymed up to $320 million
- Precision-drug maker Impact Therapeutics ignites IPO frenzy
